Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin

AKIMITSU MAEDA, HITOSHI ANDO, TAKASHI URA, KEI MURO, MASAHIRO AOKI, KEN SAITO, EISAKU KONDO, SHINJI TAKAHASHI, YUKO ITO, YASUNARI MIZUNO and AKIO FUJIMURA
Anticancer Research September 2017, 37 (9) 5235-5239;
AKIMITSU MAEDA
1Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan
2Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: m.akimitsu@aichi-cc.jp
HITOSHI ANDO
2Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI URA
3Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEI MURO
3Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAHIRO AOKI
4Division of Molecular Pathology, Aichi Cancer Center Research Institute, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEN SAITO
5Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EISAKU KONDO
5Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINJI TAKAHASHI
1Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKO ITO
1Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUNARI MIZUNO
1Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIO FUJIMURA
2Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP. Patients and Methods: We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer patients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline. Results: NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline. Conclusion: Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr.

  • N-acetyl-β-D-glucosaminidase
  • kidney injury molecule-1
  • neutrophil gelatinase-associated lipocalin
  • cisplatin
  • acute kidney injury
  • Received June 21, 2017.
  • Revision received July 1, 2017.
  • Accepted July 4, 2017.
  • Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
View Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 37 (9)
Anticancer Research
Vol. 37, Issue 9
September 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin
AKIMITSU MAEDA, HITOSHI ANDO, TAKASHI URA, KEI MURO, MASAHIRO AOKI, KEN SAITO, EISAKU KONDO, SHINJI TAKAHASHI, YUKO ITO, YASUNARI MIZUNO, AKIO FUJIMURA
Anticancer Research Sep 2017, 37 (9) 5235-5239;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin
AKIMITSU MAEDA, HITOSHI ANDO, TAKASHI URA, KEI MURO, MASAHIRO AOKI, KEN SAITO, EISAKU KONDO, SHINJI TAKAHASHI, YUKO ITO, YASUNARI MIZUNO, AKIO FUJIMURA
Anticancer Research Sep 2017, 37 (9) 5235-5239;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Acute Kidney Injury Following Hyperthermic Intraperitoneal Chemotherapy With Cisplatin
  • Google Scholar

More in this TOC Section

  • The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment
  • Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
  • Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study
Show more Clinical Studies

Similar Articles

Keywords

  • N-acetyl-β-D-glucosaminidase
  • kidney injury molecule-1
  • neutrophil gelatinase-associated lipocalin
  • Cisplatin
  • acute kidney injury
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire